Full Fed. Circ. Passes On Sarepta's Patent Rehearing Bid
By Zak Kostro · April 22, 2026, 9:04 PM EDT
The full Federal Circuit on Wednesday rejected Sarepta Therapeutics Inc.'s bid for a rehearing after a panel's decision revived a University of Pennsylvania gene therapy patent that is licensed by clinical-stage...
To view the full article, register now.